SVNTE Savient Pharmaceuticals (MM)

Savient Pharmaceuticals Inc. (NASDAQ: SVNTE), an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, today announced that Christopher Clement, President and Chief Executive Officer, will present at the Rodman & Renshaw Techvest Healthcare Conference on Wednesday, November 9, 2005 at 11:15 a.m. EST at the New York Palace Hotel. A live webcast of the presentation can be accessed under the News section of Savient's website at www.savientpharma.com and will be archived through November 23, 2005. Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be required. About Savient Pharmaceuticals, Inc. Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing, manufacturing and marketing novel therapeutic products that address unmet medical needs. The Company's lead product development candidate, Puricase(R), for the treatment of refractory gout has reported positive Phase 1 and 2 clinical data. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and initial focus in rheumatology. The Company's operations also include a wholly-owned U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops, manufactures and markets liquid formulations of prescription pharmaceutical products. Rosemont's product portfolio includes over 90 liquid formulations primarily targeting the geriatric population. Further information on the Company can be accessed by visiting www.savientpharma.com.